Clinical Trials

NantKwest and ImmunityBio to initiate a phase 2 study of immunotherapy for metastatic pancreatic cancer

NantKwest announced plans for a Phase 2, randomized, open-label study to evaluate the efficacy and safety of their combination immunotherapy: NantKwest’s PD-L1 t-haNK, ImmunityBio’s N-803, and aldoxorubicin HCI plus standard of care, versus standard-of-care chemotherapy for first- and second-line treatment of locally advanced or metastatic pancreatic cancer.

Sanofi’s blood cancer drug Sarclisa meets primary endpoint in IKEMA trial

Sanofi said that its blood cancer drug Sarclisa (isatuximab) has achieved the primary goal of a phase 3 trial in patients with relapsed multiple myeloma.

Ocular Therapeutix announces first patient dosed in phase 1 clinical trial of OTX-CSI to treat dry eye disease

Ocular Therapeutix, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patients in its Phase 1 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED).

Appili Therapeutics submits CTA with Health Canada to sponsor trial of favipiravir as preventative measure against Covid-19

Appili Therapeutics said that it will sponsor the first clinical trial evaluating FUJIFILM Toyama Chemical’s (FFTC) drug favipiravir for the prevention of COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.

India’s Glenmark begins Covid-19 trials with antiviral tablet Favipiravir

India-based Glenmark Pharmaceuticals has commenced phase 3 clinical studies on antiviral tablet Favipiravir for Covid-19 patients in the country.

Laurent Pharmaceuticals receives Health Canada’s approval to initiate Covid-19 clinical trial

Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, announced that it has obtained the approval from Health Canada to initiate RESOLUTION, a Phase 2 randomized placebo-controlled trial testing once-a-day oral LAU-7b as a potential drug candidate to help combat the COVID-19 disease.

Bicycle Therapeutics announces first patient dosed in phase I dose escalation of BT5528 in combination with nivolumab

Bicycle Therapeutics, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, announced that the first patient has been dosed in a Phase I dose escalation of BT5528 in combination with nivolumab.

Pfizer, BioNTech dose first participants in Covid-19 vaccine trial in US

Pfizer and Biopharmaceutical New Technologies (BioNTech) have dosed the first participants of a phase 1/2 trial for their Covid-19 vaccine candidate BNT162 in the US.

Default Table Multi-Parameter Transmitter M800

The M800 multi-parameter transmitter provides simultaneous monitoring of one, two or four in-line sensors. It offers measurement of pH/ORP, optical DO, amperometric oxygen (DO as well as O2 gas), conductivity, resistivity, TOC, dissolved ozone, flow and turbidity in pure water as well as process applications.